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Conclusion. Achieving rhythm control with D.C. cardioversion does not improve coagula-
tion or platelet markers in patients with AF. This study may in part explain why rate control
with anticoagulation seems superior to rhythm control in patients with AF.
1129-213 Which Patients With Atrial Fibrillation or Atrial Flutter 
Benefit From Electrical Cardioversion?
Ahmad A. Elesber, A. Gabriela Rosales, Joseph Maalouf, Nasser Ammash, David 
Hodge, Stephen C. Hammill, Paul A. Friedman, Mayo Clinic, Rochester, MN
Background: Optimal management of new onset atrial fibrillation (Afib) or flutter (Aflu) is
not known. We sought to determine the recurrence rate of atrial arrhythmia post electrical
cardioversion (DCCV) of new onset Afib and Aflu.
Methods: A cohort of 244 patients (pts) with documented Afib (119 with new onset Afib)
and 79 pts with Aflu (52 with new onset Aflu) were followed after DCCV for recurrence.
Post-surgical pts with Afib or Aflu were excluded. Cox proportional hazards models were
used to construct multivariate models.
Results: The mean age was 71.1±12.4 years with 69% being males, 30% had coronary
artery disease, 19% had congestive heart failure and 68% had hypertension. The mean
follow up was 159.5±171.2 days. Pts with recurrent Afib (57.6%) or recurrent Aflu (63%)
were more likely to be on antiarrhythmic medications than pts with new onset Afib
(19.3%) or new onset Aflu (3.9%), p<0.05. In a multivariate model, pts with a bigger right
atrial size (p=0.02) or mitral valve disease (p<0.01) were more likely to have recurrence
of atrial arrhythmia. Use of antiarrhythmic medications had no effect on recurrence. Pts
with new onset Aflu were less likely to recur after DCCV than pts with new onset Afib or
either recurrent Aflu or Afib, p<0.001 (see figure).
Conclusion: DCCV for pts with new onset Aflu is a reasonable strategy with 65% of pts
maintaining sinus rhythm at 1.5 years of follow-up. Only 20% of pts with Afib or recurrent
Aflu remained in sinus rhythm at 1.5 years of follow-up.
1129-214 Atrial Fibrillation and Heart Failure: Preserved Systolic 
Function Does Not Predict a Benign Prognosis
Ratika Parkash, F. Michael Toca, William H. Maisel, William G. Stevenson, Brigham and 
Women's Hospital, Boston, MA
Background: The prognostic significance of preserved systolic function in heart failure
(HF) and atrial fibrillation (AF) is controversial.
Methods:To determine the impact of ventricular function (EF) on mortality associated with
AF and HF data were reviewed from consecutive patients presenting to the emergency
department at Brigham and Women's Hospital from January 1998 to December 2001
who had both AF and HF and a measure of EF. Vital status was determined from the
Social Security Death Index. Survival analysis was performed.
Results: A total of 1759 patients met entry criteria (mean age 73+/-12 yrs, 44% women).
EF was preserved (>50%) in 42%. No difference in median survival was found amongst
patients with an EF > 50% (3.30 yrs, 95% CI (2.70,3.79)) compared to those with an EF
</= 50% (3.19 yrs, 95% CI (2.73,3.67))(p=0.70), even after adjustment for age, gender,
creatinine (Cr) and QRS duration. In multivariable analysis older age, male gender and
increased Cr were predictive of increased mortality.
Conclusion: Patients with atrial fibrillation, heart failure and preserved EF have similar
mortality to those with depressed EF. Further study is needed to assess the impact of
therapies and clarify the reasons for poor prognosis. 
1129-215 Energy Selection for Elective External Direct Current 
Cardioversion: A Randomized Comparison of High 
Initial Energy and Conventional Step-Up Protocol
Lana Boodhoo, George Bordoli, Andrew Mitchell, Nikhil Patel, Neil Sulke, Eastbourne 
General Hospital, Eastbourne, United Kingdom
BACKGROUND: Current guidelines recommend a step-up energy protocol for the car-
dioversion of atrial arrhythmias. The aim of this study was to compare such a protocol
with a protocol involving an initial high energy shock.
METHODS: This prospective single-blind study enrolled 261 consecutive patients (mean
age 71 ± 10 years, 62% male) referred for elective transthoracic cardioversion of persis-
tent atrial fibrillation (AF). Patients were randomised to either protocol A: (1) 200J
anteroapical (AA), (2) 360J AA, (3) 360J anteroposterior (AP) or
protocol (B): (1) 360J AA (2) 360J AP and (3) 360J posteroanterior (PA).
All procedures were performed under deep sedation with intravenous diazepam.
RESULTS: Both procedures resulted in similar success rates after the maximum of 3
shocks (A 82%, B 87%, p=0.3), however there was a highly significant increase in 1st
shock success for protocol B, 68%, versus 41% for protocol A, p<0.0001. Protocol B
resulted in significantly fewer shocks to achieve sinus rhythm as compared to protocol A
(1.3 ± 0.6 versus 1.6 ± 0.7, p=0.0002). There were no differences in cumulative energy
used (group A, 473 ± 286J, versus group B, 436 ± 273J, p=0.24) or sedation require-
ments (group A, 22 ± 9 mg, group B, 22 ± 9 mg, p=0.7).
CONCLUSION: High initial energy cardioversion for atrial fibrillation increased 1st shock
success and decreased shock frequency but resulted in similar overall conversion rates,
cumulative energy and use of sedation compared with conventional step-up protocol.
Reversal of polarity should be considered in patients who fail initial shocks.
1129-216 How Does Age Influence the Prescribing of 
Antithrombotic Therapy for Ambulatory Patients With 
Permanent Atrial Fibrillation?
Alain Leizorovicz, Maxime Guenoun, Jean Yves Le Heuzey, Claude Jeandel, Patrick 
Mismetti, Ariel Cohen, The FALSTAF Study Group, School of Medicine Laennec, Lyon, 
France
Background: . Prescription of antitrhombotics in Atrilal Fibrillation (AF) patients (pts) and
its determinants in elderly patients are not well known. We undertook a survey in ambula-
tory AF patients in France.
Methods: We prospectively surveyed consecutive outpatients with documented perma-
nent AF with or without valvular disease, excluding those with valvular prostheses. Cardi-
ologists or general practitioners were selected at random
Results: 5893 pts were included by 188 cardiologists (2367 pts) and 582 general practi-
tioners (3526 pts). Their mean age was 75.8 years, 58% were men, .31.7% had Valvular
disease.
Overall, 95.5% of pts were being prescribed an antithrombotic drug, including vitamin K
antagonists (VKA) in 76.4% of pts and aspirin in 16.6% .
Higher age was a strong predictive factor for lower prescribing of antithrombotic ther-
apy.even after multivariate adjustment for other factors with a significant negative influ-
ence on prescribing, such as poor autonomy, history of severe hemorrhage and
potentially haemorrhagic diseases.
Above 80 years, 7.4% of pts were not receiving antithrombotic prophylaxis.
Among pts receiving an antithrombotic therapy, the use of VKA decreased sharply after
75 years in favor of aspirin (figure)
Conclusions: In our study, a majority of ambulatory patients with permanent AF were
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receiving antithrombotic therapy. However, the use of VKA was not optimal in elderly
patients and better prophylactic strategies may be warranted for them .
1129-217 A Decision-Tree Model Comparing First-Line Electrical 
Cardioversion to Ibutilide With or Without Magnesium 
Prophylaxis in the Treatment of Atrial Fibrillation
Craig I. Coleman, James S. Kalus, C. Michael White, Jeffrey Kluger, University of 
Connecticut, Storrs, CT, Hartford Hospital, Hartford, CT
Background: Ibutilide is cost-effective when compared to first-line electrical cardiover-
sion (EC) for atrial fibrillation (AF); however, these results are sensitive to alterations in
conversion rate. Prophylactic magnesium augments the efficacy of ibutilide as demon-
strated by an increased rate of successful conversion. The objective of this evaluation
was to compare the costs associated with first-line EC and ibutilide in the presence and
absence of magnesium prophylaxis for the conversion of AF. Methods: A decision-tree
model was developed to estimate the cost-effectiveness of first-line EC compared to
ibutilide with or without prophylactic intravenous magnesium sulfate followed by EC in
those patients who do not convert. Conversion rates for patients receiving ibutilide with or
without magnesium were based upon results of a multi-center, retrospective, cohort
study (n=319). Healthcare utilization costs including drugs, intravenous admixture and
administration, EC, electrocardiographs and physicians’ fees were based upon actual
costs from our institution. Cost-effectiveness was calculated by multiplying the cost of a
successful and unsuccessful outcome by their probability of occurrence and then adding
these two figures to determine total cost. Results: Ibutilide+magnesium was found to be
the most cost-effective for conversion of AF (see figure). Conclusion: The decision-tree
model suggests that ibutilide+magnesium is more cost-effective than ibutilide alone or
first-line EC. 
1129-218 Ibutilide Improves Cardioversion Success Rates in 
Patients on Chronic Amiodarone Therapy With 
Persistent Atrial Fibrillation
Jenny C. Hu, Kelly Machuca, Shelley DePeralta, Bramah Singh, Zenaida Feliciano, VA 
Greater Los Angeles Healthcare System, Los Angeles, CA
Background: Atrial fibrillation (AF) is the most common arrhythmia, affecting approxi-
mately 2.2 million people in the United States. A combination of amiodarone and ibutilide
has been used with results suggesting an additive or synergistic effect on AF conversion.
Methods: We retrospectively studied 90 consecutive patients with persistent AF receiv-
ing oral amiodarone therapy who elected for electrical cardioversion. Patients underwent
either direct current cardioversion (DCC) (Group A, n=67) or DCC with ibutilide pretreat-
ment (Group B, n=23). To evaluate the effect of AF duration on DCC success rate,
patients were further divided into AF duration < 1 year (Group A1, n=30 and Group B1,
n=4) and AF duration > 1 year (Group A2, n=37 and Group B2, n=19). Chi-square analy-
sis was used to evaluate the statistical significance (set at p<0.05) between groups.
Results:
All patients were male, mostly hypertensive (86%) and age 64 ± 9.6 years, body mass
index 34 ± 8.1 kg/m2, left atrial size 52 ± 8.4 mm, ejection fraction 52 ± 10 %, and AF
duration 2.8 years ± 3.1 years. DCC success rates were 60% in Group A and 87% in
Group B (p=0.02). A trend for DCC success rate improvement with ibutilide was seen in
patients with AF duration > 1 year (Group A2=57% vs. Group B2=84%, p=0.07). One
patient in the ibutilide pretreatment group developed torsade de pointes.
Conclusion: Ibutilide pretreatment for DCC may be a safe and effective method of
improving DCC success rates in patients with long duration persistent AF receiving amio-
darone therapy. 
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1130-207 Prevalence and Spectrum of Mutations in the Cardiac 
Ryanodine Receptor in Patients Referred for Long QT 
Syndrome Genetic Testing
Laura J. Kopplin, David J. Tester, Michael J. Ackerman, Mayo Clinic, Rochester, MN
Background: Pathogenic mutations in the gene, RYR2, encoding the cardiac ryanodine
receptor cause type 1 catecholaminergic polymorphic ventricular tachycardia (CPVT1).
There is phenotypic overlap between the clinical presentation of CPVT and long QT syn-
drome (LQTS). Because the diagnosis of CPVT can be elusive, we sought to determine
the spectrum and prevalence of RYR2 mutations in a cohort of unrelated patients
referred specifically for LQTS genetic testing.
Methods: Since 1997, nearly 500 unrelated patients have been referred to Mayo Clinic’s
Sudden Death Genomics Laboratory for LQTS genetic testing. Putative pathogenic
mutations in the known LQTS-causing genes have been identified in approximately 50%
of the cases. Mutational analysis of 18 exons of RYR2 previously implicated in CPVT was
performed on genomic DNA from 240 genotype-negative subjects using polymerase
chain reaction, denaturing high performance liquid chromatography, and direct DNA
sequencing.
Results: Seventeen distinct RYR2 mutations (16 missense, 1 duplication insertion, 15
novel) were found in 20 out of 240 genotype-negative subjects (8.3%). None of these
mutations were present in 400 reference alleles. Two mutations localized to the
FKBP12.6 binding domain. Upon review of the clinical records, the referral diagnosis for
19 out of 20 patients was “atypical” or “borderline” LQTS rather than CPVT. None of the
individuals displayed diagnostic QT prolongation (QTc > 470 ms).
Conclusion: Putative pathogenic CPVT1-causing mutations in RYR2 were detected in
nearly 10% of unrelated and LQTS genotype-negative patients who were referred for
LQTS genetic testing. These findings suggest that CPVT may be under-recognized
among physicians referring patients with a suspected channelopathy. A diagnosis of
“atypical LQTS” may warrant consideration of CPVT and analysis of RYR2 if the primary
LQTS-causing channel screen is negative.
1130-208 Diagnostic Value of the Ajmaline Test Based on the 
Gene Analysis in Concealed Brugada Syndrome
Kui Hong, Kiyotaka Matsuo, Antonio Berruezo Sanchez, Matteo Vatta, Jeff Towbin, Josep 
Brugada, Pedro Brugada, Carlos Piñero Galvez, Charles Antzelevitch, Ramon Brugada, 
Masonic Medical Research Laboratory, Utica, NY
Background Brugada syndrome is an arrhythmogenic disease caused in part by muta-
tions in the cardiac sodium channel gene, SCN5A. The electrocardiogram in Brugada
syndrome is variable over time up to the point of normalization in some individuals. Diag-
nosis of possible affected individuals is performed with the use of sodium channel-block-
ing agents which unmask the EKG abnormality. However, validation of the testing has not
been performed. The use of genetic data as a gold standard in large families allows to
examine the effectiveness of ajmaline for diagnosis.
Methods We collected 4 large families with a total of 128 members. Ninety members
were relatives at possible risk of Brugada syndrome. Sixteen had a positive EKG at base-
